155 related articles for article (PubMed ID: 17130963)
1. [Effectiveness of Leuprolide acetate therapy every three months in central precocious puberty].
Mericq G MV; Youlton R R; Willshaw Z ME
Rev Med Chil; 2006 Jul; 134(7):821-6. PubMed ID: 17130963
[TBL] [Abstract][Full Text] [Related]
2. Long-term effectiveness of depot gonadotropin-releasing hormone analogue in the treatment of children with central precocious puberty.
Clemons RD; Kappy MS; Stuart TE; Perelman AH; Hoekstra FT
Am J Dis Child; 1993 Jun; 147(6):653-7. PubMed ID: 8506834
[TBL] [Abstract][Full Text] [Related]
3. Accelerated versus slowly progressive forms of puberty in girls with precocious and early puberty. Gonadotropin suppressive effect and final height obtained with two different analogs.
Lanes R; Soros A; Jakubowicz S
J Pediatr Endocrinol Metab; 2004 May; 17(5):759-66. PubMed ID: 15237711
[TBL] [Abstract][Full Text] [Related]
4. Predictors of bone maturation, growth rate and adult height in children with central precocious puberty treated with depot leuprolide acetate.
Klein KO; Dragnic S; Soliman AM; Bacher P
J Pediatr Endocrinol Metab; 2018 Jun; 31(6):655-663. PubMed ID: 29750651
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of leuprolide therapy in children with central precocious puberty.
Kappy MS; Stuart T; Perelman A
Am J Dis Child; 1988 Oct; 142(10):1061-4. PubMed ID: 3140654
[TBL] [Abstract][Full Text] [Related]
6. Importance of leuprolide acetate variable dosing for precocious puberty: a range of acceptable suppression.
Cohen D; Janfaza M; Klein KO
J Pediatr Endocrinol Metab; 2009 Jul; 22(7):629-34. PubMed ID: 19774844
[TBL] [Abstract][Full Text] [Related]
7. Long-term effects of treatment of central precocious puberty with gonadotropin-releasing hormone analogs every three months.
Vatopoulou A; Roos E; Daniilidis A; Dinas K
Gynecol Endocrinol; 2020 Dec; 36(12):1124-1126. PubMed ID: 32484003
[TBL] [Abstract][Full Text] [Related]
8. [Effect of treatment with gonadotropin releasing hormone analogues in girls with idiopathic central precocious puberty].
Ságodi L; Sólyom E; Lombay B; Almási A; Vámosi I
Orv Hetil; 2012 Mar; 153(11):418-24. PubMed ID: 22390866
[TBL] [Abstract][Full Text] [Related]
9. [Clinical study of subcutaneous administration of gonadotropin-releasing hormone agonist every six weeks in girls with idiopathic central precocious puberty].
Liang Y; Wei H; Zhang JL; Hou L; Luo XP
Zhonghua Er Ke Za Zhi; 2004 Nov; 42(11):845-9. PubMed ID: 15631714
[TBL] [Abstract][Full Text] [Related]
10. Long-term treatment of central precocious puberty with a long-acting analogue of luteinizing hormone release hormone (D-Tryp6-GnRH) in monthly injections. Its possible use in normal puberty.
Marcondes JA; Abujamra AC; Minanni SL; Mendonca BB; Nery M; Lerario AC; Pereira MA; Abelin N; Wajchenberg BL
Horm Metab Res; 1993 Feb; 25(2):105-9. PubMed ID: 8458605
[TBL] [Abstract][Full Text] [Related]
11. Monitoring treatment of central precocious puberty using basal luteinizing hormone levels and practical considerations for dosing with a 3-month leuprolide acetate formulation.
Lee PA; Luce M; Bacher P
J Pediatr Endocrinol Metab; 2016 Nov; 29(11):1249-1257. PubMed ID: 27740929
[TBL] [Abstract][Full Text] [Related]
12. Final height after combined growth hormone and gonadotrophin-releasing hormone analogue therapy in short healthy children entering into normally timed puberty.
Lanes R; Gunczler P
Clin Endocrinol (Oxf); 1998 Aug; 49(2):197-202. PubMed ID: 9828907
[TBL] [Abstract][Full Text] [Related]
13. Two-year results of treatment with depot leuprolide acetate for central precocious puberty.
Neely EK; Hintz RL; Parker B; Bachrach LK; Cohen P; Olney R; Wilson DM
J Pediatr; 1992 Oct; 121(4):634-40. PubMed ID: 1403402
[TBL] [Abstract][Full Text] [Related]
14. Elevated Random Luteinizing Hormone is an Unreliable Indicator for Pubertal Suppression in Girls Treated with Monthly Leuprolide for Idiopathic Central Precocious Puberty.
Wiromrat P; Panamonta O
J Clin Res Pediatr Endocrinol; 2019 Sep; 11(3):227-233. PubMed ID: 30592192
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of leuprolide acetate administered monthly compared to three-monthly in the treatment of central precocious puberty: evaluation at the end of treatment.
Thaneetrakool T; Aroonparkmongkol S; Numsriskulrat N; Supornsilchai V; Wacharasindhu S; Srilanchakon K
Front Endocrinol (Lausanne); 2024; 15():1390674. PubMed ID: 38737553
[TBL] [Abstract][Full Text] [Related]
16. Luteinizing hormone (LH) and estradiol suppression and growth in girls with central precocious puberty: is more suppression better? Are pre-injection LH levels useful in monitoring treatment?
Kunz GJ; Sherman TI; Klein KO
J Pediatr Endocrinol Metab; 2007 Nov; 20(11):1189-98. PubMed ID: 18183790
[TBL] [Abstract][Full Text] [Related]
17. Suppression of gonadotropin secretion by a long-acting gonadotropin-releasing hormone analog (leuprolide acetate, Lupron Depot) in children with precocious puberty.
Kappy M; Stuart T; Perelman A; Clemons R
J Clin Endocrinol Metab; 1989 Nov; 69(5):1087-9. PubMed ID: 2507570
[TBL] [Abstract][Full Text] [Related]
18. Treatment with Depot Leuprolide Acetate in Girls with Idiopathic Precocious Puberty: What Parameter should be Used in Deciding on the Initial Dose?
Vurallı D; Alikaşifoğlu A; İyigün İ; Canoruç D; Ozon A; Gönç N; Kandemir N
J Clin Res Pediatr Endocrinol; 2020 Mar; 12(1):37-44. PubMed ID: 31347350
[TBL] [Abstract][Full Text] [Related]
19. 36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty.
Lee PA; Klein K; Mauras N; Lev-Vaisler T; Bacher P
J Clin Endocrinol Metab; 2014 Sep; 99(9):3153-9. PubMed ID: 24926950
[TBL] [Abstract][Full Text] [Related]
20. Phase 3 Trial of a Small-volume Subcutaneous 6-Month Duration Leuprolide Acetate Treatment for Central Precocious Puberty.
Klein KO; Freire A; Gryngarten MG; Kletter GB; Benson M; Miller BS; Dajani TS; Eugster EA; Mauras N
J Clin Endocrinol Metab; 2020 Oct; 105(10):e3660-71. PubMed ID: 32738042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
